Andree Blaukat

Merck (Germany) — Germany

Medicine · Health Sciences

34h-index4.7kcitations334works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(67), Cancer Research and Treatments(67), Liver physiology and pathology(60), Neuroendocrine Tumor Research Advances(39), DNA Repair Mechanisms(32)

Publications334 total

Supplementary Data from Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors
2025Open Access
Supplementary Table S5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Figure 2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S8 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Data from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Figure S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Figure 6 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025· 1 citedOpen Access
Supplementary Table S1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S9 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Figure 3 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S10 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Figure S5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Figure S1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Figure 5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S6 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
Supplementary Table S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Werner Müller‐Esterl(10), Friedhelm Bladt(9), Ivan Đikić(8), Frank T. Zenke(6), Michaela Medová(6), Daniel M. Aebersold(6), Yitzhak Zimmer(6), Astrid Zimmermann(4), Ulrich Pehl(4), Manja Friese‐Hamim(4), Anne Pizard(4), François Alhenc‐Gelas(4), Evi Kostenis(4), Lluís Nisa(4), Deborah Stroka(4), Sorin Tunaru(3), Claudia Wilm(3), Ulrich Grädler(3), Thomas Benzing(3), Rabary M. Rajerison(3)